Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Analysis of Immunohistochemical Markers in Bone Marrow Sections to Evaluate for Myelodysplastic Syndromes and Acute Myeloid Leukemias

Analysis of Immunohistochemical Markers in Bone Marrow Sections to Evaluate for Myelodysplastic... RESEARCH ARTICLE Analysis of Immunohistochemical Markers in Bone Marrow Sections to Evaluate for Myelodysplastic Syndromes and Acute Myeloid Leukemias Cherie H. Dunphy, MD,* Dennis P. O’Malley, MD,w Sherrie L. Perkins, MD, PhD,z and Chung-Che Chang, MDy combination, they are most reliable and should be performed on Background: Accurate bone marrow (BM) blast counts (BCs) BM clots/cores due to variable reactivity. are essential for diagnosis (dx) of myelodysplasia (MDS), MDS/ Key Words: immunohistochemistry, AML, myelodysplasia, myeloproliferative (MDS/MPD) disease, or acute myeloid CD34, CD117, HbA1, terminal deoxynucleotidyl transferase, leukemia (AML), and may be difficult in hemodiluted bone myeloperoxidase marrow aspirates (BMAs). Erythroid precursors (EPs) may be indistinguishable from myeloblasts in BM sections (aspirate clots/ (Appl Immunohistochem Mol Morphol 2007;15:154–159) cores). We compare the usefulness of immunohistochemistry (IHC) [ie, CD34, CD117, myeloperoxidase (MPO), Hemoglobin A1 (HbA1), and terminal deoxynucleotidyl transferase (TdT)] of BM sections (IHC-BM) with BMA, bone marrow touch t may be difficult to determine an accurate percentage of preparation (BMTP), and flow cytometry (FC) BCs. Imyeloblasts to establish a diagnosis of myelodysplasia (MDS) or acute myeloid leukemia (AML) based on a Design: The initial BC (48), percentage (%) of Eps (38) (both bone marrow (BM) aspirate alone. This is particularly http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Analysis of Immunohistochemical Markers in Bone Marrow Sections to Evaluate for Myelodysplastic Syndromes and Acute Myeloid Leukemias

Loading next page...
 
/lp/wolters-kluwer-health/analysis-of-immunohistochemical-markers-in-bone-marrow-sections-to-tZx0d4Vf2s
ISSN
1541-2016
DOI
10.1097/PAI.0b013e318030dec7
pmid
17525626
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE Analysis of Immunohistochemical Markers in Bone Marrow Sections to Evaluate for Myelodysplastic Syndromes and Acute Myeloid Leukemias Cherie H. Dunphy, MD,* Dennis P. O’Malley, MD,w Sherrie L. Perkins, MD, PhD,z and Chung-Che Chang, MDy combination, they are most reliable and should be performed on Background: Accurate bone marrow (BM) blast counts (BCs) BM clots/cores due to variable reactivity. are essential for diagnosis (dx) of myelodysplasia (MDS), MDS/ Key Words: immunohistochemistry, AML, myelodysplasia, myeloproliferative (MDS/MPD) disease, or acute myeloid CD34, CD117, HbA1, terminal deoxynucleotidyl transferase, leukemia (AML), and may be difficult in hemodiluted bone myeloperoxidase marrow aspirates (BMAs). Erythroid precursors (EPs) may be indistinguishable from myeloblasts in BM sections (aspirate clots/ (Appl Immunohistochem Mol Morphol 2007;15:154–159) cores). We compare the usefulness of immunohistochemistry (IHC) [ie, CD34, CD117, myeloperoxidase (MPO), Hemoglobin A1 (HbA1), and terminal deoxynucleotidyl transferase (TdT)] of BM sections (IHC-BM) with BMA, bone marrow touch t may be difficult to determine an accurate percentage of preparation (BMTP), and flow cytometry (FC) BCs. Imyeloblasts to establish a diagnosis of myelodysplasia (MDS) or acute myeloid leukemia (AML) based on a Design: The initial BC (48), percentage (%) of Eps (38) (both bone marrow (BM) aspirate alone. This is particularly

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jun 1, 2007

There are no references for this article.